← Trials/Trial dossier/NCT03883412
ZQL007
UnknownPhase 4Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
Lead sponsor
Asset
Liraglutide
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
1
Enrollment
60
estimated
Study population
Type 2 diabetes
Key I/E criterion
•HbA1c ≤8.5%
Primary endpoint
•Microvascular Blood Volume - change
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (6)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Glycemic / diabetes
1 endpointInsulin Sensitivity-Change from baseline
Time frame:16 weeks
HOMA-IR (insulin sensitivity)
change from baseline, improvement
Cardiometabolic biomarkers
3 endpointsAugmentation Index - change from baseline
Time frame:16 weeks
change from baseline, improvement
Flow Mediated Dilation - change from baseline
Time frame:16 weeks
change from baseline, improvement
Pulse Wave Velocity - change from baseline
Time frame:16 weeks
change from baseline, improvement
Other (unclassified)
2 endpointsMicrovascular Blood Volume - change from baseline
Time frame:16 weeks
change from baseline, descriptive
Post Ischemic Flow Velocity-Change from baseline
Time frame:16 weeks
change from baseline, descriptive
Publications (44)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- American journal of physiology. Endocrinology and metabolism2014 Dec 15PMID25352432doi:10.1152/ajpendo.00020.2014via CT.gov background
- Journal of cardiology2014 Aug (month)PMID24438856doi:10.1016/j.jjcc.2013.12.002via CT.gov background
- Microcirculation (New York, N.Y. : 1994)2014 May (month)PMID24450403doi:10.1111/micc.12117via CT.gov background
- Journal of vascular surgery2012 Oct (month)PMID23026425doi:10.1016/j.jvs.2012.04.046via CT.gov background
- Diabetes, obesity & metabolism2012 Aug (month)PMID22429614doi:10.1111/j.1463-1326.2012.01598.xvia CT.gov background
- Journal of applied physiology (Bethesda, Md. : 1985)2011 Jul (month)PMID21512146doi:10.1152/japplphysiol.00141.2011via CT.gov background
- Atherosclerosis2011 Jul (month)PMID21481871doi:10.1016/j.atherosclerosis.2011.03.018via CT.gov background
- The Journal of clinical endocrinology and metabolism2011 Feb (month)PMID21047922doi:10.1210/jc.2010-1174via CT.gov background
- Hypertension (Dallas, Tex. : 1979)2010 Feb (month)PMID19996061doi:10.1161/HYPERTENSIONAHA.109.145409via CT.gov background
- The Journal of clinical endocrinology and metabolism2009 Sep (month)PMID19567533doi:10.1210/jc.2009-0027via CT.gov background
- The Journal of physiology2009 Apr 15PMID19237429doi:10.1113/jphysiol.2008.164384via CT.gov background
- JACC. Cardiovascular imaging2008 May (month)PMID19356447doi:10.1016/j.jcmg.2008.04.001via CT.gov background
- American journal of physiology. Endocrinology and metabolism2006 Jun (month)PMID16682488doi:10.1152/ajpendo.00497.2005via CT.gov background
- The Journal of pharmacology and experimental therapeutics2006 Jun (month)PMID16489128doi:10.1124/jpet.106.100982via CT.gov background
- Nature reviews. Molecular cell biology2006 May (month)PMID16633338doi:10.1038/nrm1911via CT.gov background
- American journal of physiology. Heart and circulatory physiology2005 Aug (month)PMID15792994doi:10.1152/ajpheart.00092.2005via CT.gov background
- Arteriosclerosis, thrombosis, and vascular biology2005 May (month)PMID15863720doi:10.1161/01.ATV.0000164044.42910.6bvia CT.gov background
- Journal of applied physiology (Bethesda, Md. : 1985)2005 Jan (month)PMID15298982doi:10.1152/japplphysiol.00353.2004via CT.gov background
- American journal of physiology. Heart and circulatory physiology2004 Nov (month)PMID15059773doi:10.1152/ajpheart.00067.2004via CT.gov background
- American journal of physiology. Endocrinology and metabolism2004 Oct (month)PMID15213062doi:10.1152/ajpendo.00077.2004via CT.gov background
- Physiological genomics2004 Jun 17PMID15084712doi:10.1152/physiolgenomics.00023.2004via CT.gov background
- American journal of physiology. Endocrinology and metabolism2003 Jul (month)PMID12791603doi:10.1152/ajpendo.00021.2003via CT.gov background
- Cardiovascular research2002 Dec (month)PMID12445887doi:10.1016/s0008-6363(02)00593-xvia CT.gov background
- The American journal of cardiology2001 Feb 1PMID11165969doi:10.1016/s0002-9149(00)01367-9via CT.gov background
- The Journal of clinical investigation1999 Aug (month)PMID10449437doi:10.1172/JCI5971via CT.gov background
- The Journal of clinical investigation1987 Aug (month)PMID3301899doi:10.1172/JCI113088via CT.gov background
- The American journal of physiology1982 Aug (month)PMID7114231doi:10.1152/ajpheart.1982.243.2.H196via CT.gov background
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.